Muscle Owl Talks Ep76: Fast Track - Accelerated Access Pathway
The UK government announced a new Fast Track scheme for breakthrough drugs. While more clarity is needed, this is a good start. Join us...
AMO Pharma: Encouraging Phase II Results for Congenital and Juvenile Myotonic Trial.
AMO Pharma has announced results from its ongoing phase II study investigating two doses of tideglusib (AMO-02) in adults with congenital...
What is EAMS and how could it help men with Duchenne muscular dystrophy in the UK?!
In episode 59 of our weekly chat show Muscle Owl Talks, we hosted Action Duchenne CEO, Diana Ribeiro, to discuss the Early Access to...
Muscle Owl Talks Ep53: Spinraza Delay in UK?! SMA Treatment (June 2017)
Late night edition Muscle Owl Talks! We discuss the latest regarding SMA and Spinraza (nusinersen) in the UK. 70 children still not on...
Muscle Owl Talks Ep46: Spinraza Approved for All Types of SMA by EMA (Europe)
On Friday we received the news that Spinraza - the latest (and first) treatment for spinal muscular atrophy - had been approved by the...
